NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer.
暂无分享,去创建一个
David Bonekamp | Kortine Kleinheinz | Matthias Schlesner | Barbara Hutter | Sebastian Uhrig | Christof von Kalle | Benedikt Brors | Peter Horak | Frank Bergmann | Volker Endris | Wilko Weichert | Barbara Klink | Lars Feuerbach | Stefan Fröhling | Albrecht Stenzinger | Daniela Richter | Christoph Heining | Martina Fröhlich | Michael Bitzer | Roland Penzel | Hanno Glimm | Claudia Scholl | Katja Steiger | C. von Kalle | S. Fröhling | E. Schröck | W. Weichert | A. Stenzinger | R. Penzel | B. Hutter | M. Schlesner | D. Bonekamp | B. Brors | B. Klink | N. Giese | C. Scholl | P. Horák | C. Heining | M. Fröhlich | S. Uhrig | D. Richter | V. Endris | H. Glimm | U. Toprak | K. Kleinheinz | F. Bergmann | C. Springfeld | M. Bitzer | K. Steiger | L. Feuerbach | C. Ball | T. Hackert | O. Strobel | Evelin Schröck | Nathalia A Giese | Thilo Hackert | Oliver Strobel | Claudia R Ball | Karl Roland Ehrenberg | Christoph Springfeld | N. Malek | Paula L Codo | Stephanie Frank | Umut H Toprak | Ranadip Mandal | Lothar Schulz | Helmut Lambertz | Sebastian Fetscher | Nisar P Malek | Marius Horger | M. Horger | S. Frank | S. Fetscher | R. Mandal | L. Schulz | H. Lambertz | K. R. Ehrenberg | Ranadip Mandal
[1] E. Pleasance,et al. Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] R. Hofheinz,et al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] C. von Kalle,et al. Precision oncology based on omics data: The NCT Heidelberg experience , 2017, International journal of cancer.
[4] Jürgen Weitz,et al. Succession of transiently active tumor‐initiating cell clones in human pancreatic cancer xenografts , 2017, EMBO molecular medicine.
[5] S. Fröhling,et al. Cooperation of BRAFF595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling , 2016, Leukemia.
[6] Eric Talevich,et al. CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing , 2016, PLoS Comput. Biol..
[7] R. Gibbs,et al. Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.
[8] A. Larsen,et al. Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status , 2016, Targeted Oncology.
[9] Kaoru Tanaka,et al. The pan-HER family tyrosine kinase inhibitor afatinib overcomes HER3 ligand heregulin-mediated resistance to EGFR inhibitors in non-small cell lung cancer , 2015, Oncotarget.
[10] A. Harris,et al. Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer , 2015, Oncotarget.
[11] Ayala Hubert,et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Benjamin D. Smith,et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.
[13] L. Mileshkin,et al. Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging. , 2014, The oncologist.
[14] I. Petersen,et al. CD74-NRG1 fusions in lung adenocarcinoma. , 2014, Cancer discovery.
[15] David Goldstein,et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.
[16] V. Heinemann,et al. KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer , 2013, Journal of Gastroenterology.
[17] C. Sotiriou,et al. Pertuzumab: new hope for patients with HER2-positive breast cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] U. Mansmann,et al. EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104 , 2012, British Journal of Cancer.
[19] Thomas R. Gingeras,et al. STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..
[20] H. Ji,et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Michael C. Rusch,et al. CREST maps somatic structural variation in cancer genomes with base-pair resolution , 2011, Nature Methods.
[22] Pierre Michel,et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.
[23] J. Shipley,et al. Lapatinib and Gemcitabine for Metastatic Pancreatic Cancer: A Phase II Study , 2009, American journal of clinical oncology.
[24] K. Sekiguchi,et al. Direct Binding of the EGF-like Domain of Neuregulin-1 to Integrins (αvβ3 and α6β4) Is Involved in Neuregulin-1/ErbB Signaling* , 2010, The Journal of Biological Chemistry.
[25] Aaron R. Quinlan,et al. Bioinformatics Applications Note Genome Analysis Bedtools: a Flexible Suite of Utilities for Comparing Genomic Features , 2022 .
[26] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[27] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[28] M. Tsao,et al. Human pancreatic duct epithelial cell model for KRAS transformation. , 2008, Methods in enzymology.
[29] P. Murawa,et al. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] D. Iannitti,et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. , 2001, Cancer investigation.
[31] Douglas L Falls,et al. Neuregulins: functions, forms, and signaling strategies. , 2003, Experimental cell research.
[32] L. Cantley,et al. Ligand Discrimination in Signaling through an ErbB4 Receptor Homodimer* , 2000, The Journal of Biological Chemistry.
[33] L. Ailles,et al. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences , 2000, Nature Genetics.
[34] E. Peles,et al. ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms. , 1994, The Journal of biological chemistry.